How Much Does Prometrium Cost in Rhode Island in 2026?

Rhode Island Retail Pricing for Prometrium in 2026

The average cash-pay cost for a 30-day supply of Prometrium at Rhode Island retail pharmacies sits near $45 in 2026, well below the AbbVie list price of roughly $180 per month. That gap exists because generic micronized progesterone capsules have been available since 2006. Generics account for the majority of fills statewide.

Prices fluctuate by pharmacy. A CVS in Providence may charge a different cash price than an independent pharmacy in Warwick or Cranston. Discount aggregators such as GoodRx and SingleCare can push a 30-capsule supply of generic micronized progesterone 100 mg below $30 at some locations. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial established micronized progesterone as a preferred progestin for endometrial protection in women receiving estrogen therapy, and prescribing patterns in Rhode Island reflect that preference 1. Before paying full cash price, patients should compare at least three pharmacies.

Rhode Island has no state-level drug price cap specific to hormone therapy. Pricing follows standard pharmacy benefit manager (PBM) reimbursement rates, which vary by contract. Patients without insurance should ask the dispensing pharmacist for the lowest available price before the transaction is processed, because the uninsured cash rate and the adjudicated price sometimes differ by $10 or more.

Compounded Micronized Progesterone in Rhode Island

Compounded micronized progesterone from a licensed 503A pharmacy in Rhode Island costs approximately $25 per month. That is roughly half the average retail price of the manufactured generic.

Rhode Island permits 503A compounding under both state pharmacy law and federal section 503A of the FD&C Act. A prescriber writes a patient-specific prescription, the compounding pharmacy fills it using USP-grade micronized progesterone powder, and the product ships or is picked up locally. Several 503A pharmacies operate within state lines, and out-of-state 503A pharmacies may also ship into Rhode Island if they hold the required nonresident pharmacy license from the Rhode Island Department of Health.

The FDA differentiates 503A (patient-specific) from 503B (outsourcing facility) compounding 2. Both pathways are legal in Rhode Island. Patients choosing compounded progesterone should confirm their pharmacy holds a current state license and follows USP 795 or USP 797 standards for non-sterile and sterile preparations, respectively.

One clinical consideration: compounded capsules do not undergo the same bioequivalence testing required for FDA-approved generics. The PEPI trial data supporting endometrial safety used the branded Prometrium formulation 1. Prescribers who switch patients to compounded versions should monitor endometrial response with periodic ultrasound or biopsy if the patient is on combined estrogen-progesterone therapy, consistent with the Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy 3.

Rhode Island Medicaid Coverage for Prometrium

Rhode Island Medicaid covers Prometrium (brand and generic micronized progesterone) with prior authorization (PA). The PA requirement means the prescriber's office must submit clinical justification to the state's Medicaid managed care organization before the pharmacy can dispense the drug at the Medicaid-covered copay.

The typical Medicaid copay for a preferred generic in Rhode Island is $1 to $3 per fill. If the PA is approved, patients pay only this nominal amount. Denials can be appealed through the standard Medicaid fair hearing process.

Rhode Island's Medicaid program operates primarily through managed care under Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare Community Plan. Each plan maintains its own preferred drug list (PDL). Generic micronized progesterone appears on most Rhode Island Medicaid PDLs as a covered agent for secondary amenorrhea and endometrial hyperplasia prevention in postmenopausal women receiving estrogen 4. Patients enrolled in fee-for-service Medicaid (a small subset) follow the state PDL directly.

To secure PA approval, the prescriber generally must document one of two FDA-approved indications: prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogens, or treatment of secondary amenorrhea. Off-label use for luteal phase support in fertility treatment may require additional documentation.

Commercial Insurance Coverage Across Rhode Island

Most commercial insurance plans available in Rhode Island place generic micronized progesterone on Tier 1 or Tier 2 of their pharmacy formularies. That translates to copays between $5 and $25 per fill for a 30-day supply, depending on the plan.

Blue Cross Blue Shield of Rhode Island (BCBSRI), the state's largest commercial insurer, covers generic micronized progesterone without prior authorization on most plans. Brand-name Prometrium may require step therapy or PA, meaning the patient must try and fail the generic before the brand is approved. Patients who experience adverse effects on a particular generic manufacturer's formulation can request a medical exception for brand-name coverage.

Employer-sponsored plans vary widely. Self-insured employer plans (which cover a substantial portion of Rhode Island's commercially insured population) are governed by ERISA, not state insurance mandates. Their formulary decisions are plan-specific. Patients should call the member services number on the back of their insurance card and ask three questions: Is micronized progesterone on the formulary? Which tier? Is prior authorization or step therapy required?

The 2022 Rhode Island mandate requiring coverage of "medically necessary hormone therapy" (RIGL 27-20.1) applies to state-regulated fully insured plans 5. This mandate supports coverage arguments for micronized progesterone prescribed as part of menopausal hormone therapy.

How the AbbVie Savings Card Works in Rhode Island

AbbVie (which acquired Solvay's progesterone portfolio) offers a manufacturer savings card for brand-name Prometrium that can reduce out-of-pocket costs for commercially insured patients. The card typically brings copays down to $0 to $25 per fill, depending on plan structure.

Eligibility rules are standard across all 50 states, including Rhode Island. Patients must have commercial insurance. Government-insured patients (Medicaid, Medicare Part D, Tricare, VA) are not eligible. The card cannot be combined with other manufacturer coupons, and it carries an annual or per-fill cap (terms change periodically, so patients should check the current offer at the AbbVie website or ask their pharmacist to run the card at point of sale).

Rhode Island does not prohibit copay accumulator or copay maximizer programs, so some employer plans may implement these. Under a copay accumulator design, the value of the manufacturer card does not count toward the patient's annual deductible or out-of-pocket maximum. Patients should verify their plan's accumulator policy before relying on the savings card as a long-term cost strategy.

Telehealth Access to Prometrium in Rhode Island

Rhode Island permits telehealth prescribing of Prometrium and generic micronized progesterone. No in-person visit is required for the initial prescription as long as the prescriber conducts an adequate clinical evaluation via synchronous audio-video encounter.

Rhode Island enacted permanent telehealth parity legislation in 2021 (RIGL 27-81), requiring insurers to cover telehealth services at the same rate as in-person visits. This applies to evaluation and management visits during which hormone therapy is prescribed. A Providence-based patient can see a Rhode Island-licensed prescriber via video, receive a micronized progesterone prescription electronically, and fill it at any Rhode Island pharmacy or a licensed mail-order pharmacy.

The practical benefit is clear. Patients in rural Washington County or Block Island, who might otherwise drive 45 minutes or more for a specialist visit, can access hormone therapy management remotely. HealthRX and similar telehealth platforms operate in Rhode Island under these rules. Prescriptions are sent electronically to the patient's preferred pharmacy.

The American College of Obstetricians and Gynecologists (ACOG) supports telehealth for ongoing hormone therapy management and considers it appropriate for established patients and, in many cases, new patients when a thorough history and symptom assessment can be completed remotely 6.

Prometrium vs. Generic Micronized Progesterone: Is There a Difference?

The FDA-approved generic micronized progesterone capsules are rated AB to Prometrium, meaning they meet bioequivalence standards. Absorption, peak serum levels, and area under the curve fall within the 80% to 125% confidence interval required by the FDA 4.

Clinically, most patients notice no difference. Some report subjective variation in sedation intensity between manufacturers, likely related to differences in inactive ingredients or dissolution rates that remain within approved bioequivalence ranges. The sedating effect of oral micronized progesterone (mediated by the allopregnanolone metabolite) is the reason bedtime dosing is standard.

The cost difference is significant. Brand Prometrium at list price runs $180 per month. The generic averages $45 at Rhode Island retail pharmacies and as low as $25 from discount platforms. Unless a patient has a documented intolerance to a specific generic formulation's inactive ingredients (such as peanut oil, present in some but not all formulations), there is no clinical reason to insist on brand over generic.

Patients with peanut allergies should note that the original Prometrium formulation contains peanut oil. Some generic versions use alternative oils. The prescriber should specify a peanut-free formulation if the allergy is documented 4.

Strategies to Minimize Your Prometrium Cost in Rhode Island

A structured approach to cost reduction can drop monthly spending from $180 down to $25 or less.

Step 1: Confirm your insurance formulary status. Call member services. Generic micronized progesterone on Tier 1 means a $5 to $10 copay.

Step 2: Compare pharmacy prices. Use GoodRx, RxSaver, or SingleCare to compare retail cash prices at CVS, Walgreens, Walmart, and independent Rhode Island pharmacies. Prices for the same drug at pharmacies within a two-mile radius can differ by $15 or more.

Step 3: Consider a 503A compounded option. If you are uninsured or underinsured, a licensed Rhode Island 503A compounding pharmacy may fill micronized progesterone capsules for approximately $25 per month. Verify the pharmacy's licensure through the Rhode Island Board of Pharmacy.

Step 4: Apply manufacturer or nonprofit assistance. The AbbVie savings card covers brand-name Prometrium for commercially insured patients. NeedyMeds and RxAssist maintain databases of patient assistance programs for progesterone products.

Step 5: Ask about 90-day fills. Many insurance plans and discount programs offer a per-unit cost reduction for 90-day supplies. A 90-day fill at a mail-order pharmacy may cost the same as two monthly fills at retail.

The PEPI trial demonstrated that micronized progesterone 200 mg for 12 days per 28-day cycle provided endometrial protection equivalent to medroxyprogesterone acetate 10 mg, with a more favorable lipid profile 1. This clinical advantage, combined with Rhode Island's competitive generic pricing, makes micronized progesterone a cost-effective choice for endometrial protection in the state.

Clinical Context: Why Micronized Progesterone Matters for HRT

Progesterone opposition of estrogen is not optional for women with a uterus on hormone therapy. Unopposed estrogen increases endometrial cancer risk by 2- to 10-fold depending on dose and duration, according to data from the Women's Health Initiative and earlier observational studies 7.

Micronized progesterone became the preferred progestin after the PEPI trial (N=875) showed it protected the endometrium while preserving estrogen's beneficial effects on HDL cholesterol. Medroxyprogesterone acetate (MPA), by contrast, blunted HDL gains by approximately 50% 1. The French E3N cohort study (N=80,377) later associated micronized progesterone with a lower breast cancer risk compared to synthetic progestins over a mean follow-up of 8.1 years 8.

The Endocrine Society's clinical practice guideline on menopausal hormone therapy recommends micronized progesterone as a first-line progestational agent for endometrial protection, citing both the PEPI lipid data and the observational breast safety signal 3.

Dr. JoAnn Manson, principal investigator of the Women's Health Initiative hormone trials, has stated: "Micronized progesterone appears to have a more favorable safety profile than synthetic progestins, particularly regarding breast cancer risk and cardiovascular markers" 7.

The North American Menopause Society (NAMS) 2022 position statement echoes this preference, noting that "the use of micronized progesterone or the atypical progestin dydrogesterone may be associated with less risk than other progestins" 9.

Rhode Island-Specific Regulatory Notes

Rhode Island's Board of Pharmacy regulates all in-state compounding pharmacies under RIGL Title 5, Chapter 19.1. Out-of-state pharmacies shipping compounded progesterone into Rhode Island must hold a nonresident pharmacy license. The Board conducts inspections aligned with USP chapter requirements.

Rhode Island does not impose a state-level surcharge or special tax on compounded hormone preparations. The state's 7% sales tax generally exempts prescription drugs, including compounded medications dispensed on a valid prescription.

For Medicaid patients, the Rhode Island Executive Office of Health and Human Services (EOHHS) publishes PDL updates quarterly. Patients or prescribers can check current coverage status through the NHPRI or UnitedHealthcare Community Plan provider portals.

A 90-day supply of generic micronized progesterone 100 mg (90 capsules) through a Rhode Island mail-order pharmacy with commercial insurance typically costs $10 to $30 in copays, making it one of the most affordable hormone therapy components available in the state.